At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Hydroxyurea Adherence for Personal Best in Sickle Cell Disease (HABIT): Efficacy Trial
In Brief
A clinical study evaluating HABIT Intervention, Standard of Care, and 1 other intervention for Sickle Cell Disease. Completed, enrolled 50 participants across 4 sites.
Detailed Summary
Many youth with chronic disease have difficulty taking medication every day and therefore do not receive full benefit from treatment. Sickle Cell Disease (SCD) is an inherited blood disease that affects African Americans and other underserved communities. Hydroxyurea (HU) is the sole FDA-approved drug therapy for SCD and is highly effective and improves quality of life. The proposed study, a 5-site four-year randomized control trial (RCT), builds upon the investigators' recent feasibility study of the same title. Overall goals are reducing barriers to HU use and improving adherence for youth 10-18 years through creation of a daily medication habit. The goal of the proposed multi-site study is to test the efficacy of the HABIT intervention at 6 months and sustainability of the effect at 12 months.
Study Details
Timeline
Interventions
Dyads randomized to the intervention group will receive the HABIT intervention, which includes CHW support and tailored text messages.
Standard of care used to treat patients with SCD
Education materials provided to all patients enrolled in the trial